Embodiments of the present application relate to batches of bupivacaine multivesicular liposomes (MVLs) prepared by a commercial manufacturing process using independently operating dual tangential flow filtration modules.

A safety device for a single-use mixing or storage system (10), especially for use in a biopharmaceutical process, includes a flexible bag (12) made from a film material and a support structure (14) receiving and supporting the bag (12) in several directions. The support structure (14) allows an expansion of the bag (12) in an expansion direction. The safety device further includes a detection unit (20) adapted to detect an expansion of the bag (12) in the expansion direction, and a control unit (28) connected to the detection unit (20) and adapted to initiate a safety measure in response to the expansion of the bag (12) in the expansion direction that exceeds a given threshold.

Embodiments of the present application relate to batches of bupivacaine multivesicular liposomes (MVLs) prepared by a commercial manufacturing process using independently operating dual tangential flow filtration modules.

A method and system for converting a single-use liner lined bottom-mix mixing vessel to a single-use liner lined top-mix missing vessel. A bottom mount magnetic impeller drive is replaced by a top mounted impeller drive. A support frame is placed on an upper portion of the mixing vessel and has an articulated joint supporting a motor drive assembly. A top-mix single-use liner is inserted into the mixing vessel. An impeller drive shaft is inserted through a rotary hub seal in the liner to drive an internal impeller. The rotary hub seal is located by a hub lock assembly attached to the motor drive assembly.

A method for encapsulating active ingredients in liposomes having an active ingredient solution encapsulated with a bilayer composed of two monomolecular layers of amphiphilic compounds comprises: (a) providing the active ingredient solution; (b) providing an emulsion by emulsifying the active ingredient solution in a first liquid in the presence of the amphiphilic compound; (c) providing a liquid phase; (d) contacting the emulsion with the liquid phase to form a phase boundary; and (e) centrifuging the emulsion and the liquid phase that are in contact with one another via the phase boundary, wherein, on passage of the phase boundary, the amphiphilic compound enriched there is added onto the monomolecular inner layer to form a monomolecular outer layer, in order to create the bilayer. The first liquid of the emulsion is chosen such that the solubility of the amphiphilic compound in the first liquid is not more than 110.sup.4 mol/l.

A tube management system includes an elongated rack extending between a first end and an opposing second end; an elongated first shaft having a first end and an opposing second end, the first shaft being secured to the rack; a securing structure secured to the first shaft; a collapsible bag bounding a chamber; and a tubular member projecting from the collapsible bag, wherein the securing structure at least partially encircles the tubular member.

Embodiments of the present application relate to compositions bupivacaine multivesicular liposomes (MVLs) prepared by a commercial manufacturing process with large particle diameter span.

A system forms a cosmetic composition. The system includes a dispensing arrangement in selective fluid communication with a plurality of dispensing dosing receptacles mounted on a movable carousel. The dispensing arrangement is configured to selectively dispense a plurality of the booster compositions together with a base composition corresponding to a formulation corresponding to a compatibility profile and consumer skin conditions to form a stable composition having efficacious concentrations of active ingredients into a receiving receptacle.

Systems and method for producing a small-scale mixer are provided. In some implementations, a method for includes obtaining dimensions of an at-scale mixer. The method also includes determining first dimensions of the small-scale mixer based on respective dimensions of the at-scale mixer. The method further includes determining second dimensions of the small-scale mixer independent of the dimensions of the at-scale mixer. Additionally, the method includes generating the small-scale mixer using the first dimensions and the second dimensions using a three-dimensional printer.

The present invention relates inter alia to a continuous process for producing an immunogenic composition using a micro-fluidic or milli-fluidic (MF) system and filling one or more vessels with the immunogenic composition.